Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cilgavimab/tixagevimab

A combination of two neutralizing human monoclonal antibodies cilgavimab and tixagevimab, that are isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration of cilgavimab/tixagevimab, both antibodies specifically target and bind to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-SARS-CoV-2 spike protein monoclonal antibody AZD7442
AZD8895 + AZD1061
AZD8895/AZD1061
monoclonal antibody AZD7442
US brand name:Evusheld
Code name:AZD 7442
AZD-7442
AZD7442
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search